Connect with us

Politics

Expert WHO Committee to Review AstraZeneca Vaccine After Worrying Side Effects Appear

Published

on

[ad_1]

Even amid concerns that have led to an increasing number of countries to stop the distribution of the COVID-19 vaccine produced by AstraZenecaa, the World Health Organization urges its continued use.

The WHO global adviser on vaccine safety reviewed the reports swollen blood that appeared in individuals who had had the shots, WHO spokeswoman Margaret Harris said, according to Reuters.

“It’s very important that we hear the safety signals because if we don’t hear about the safety signals that would suggest that there isn’t adequate monitoring and surveillance,” he said.

Mariangela Simao, WHO’s assistant director general, said on Friday that the shots were considered safe despite reports of the precipitate, according to The Washington Post.

In some cases, fatalities have been reported from coagulation, but no direct link to vaccinations has been proven, The Post reported.

“We should continue vaccination until we are clear on the causal link,” Simao said, according to The Post.

“People are dying every day. There are vaccinated people who die from other reasons.”

But that kind of logic has disappeared in concerned countries after reports that three health care workers in Norway were hospitalized with blood clots after receiving the AstraZeneca vaccine.

The Post reported that fatal blood clots had been reported in individuals who received the vaccine in Austria, Denmark and Italy.

Ireland is one of the latest countries to temporarily stop using the vaccine, ordering a pause in its use on Sunday, according to the UK-based Malaya.

“The European Medicines Agency (EMA) is already investigating numerous reports of thromboembolic (blood clotting) events following vaccination with Covid-19 Vaccine AstraZeneca,” said a statement from the Irish Department of Health, corresponding to the Independent. “More information is expected from the EMA in the coming days, which will include a review of additional events.”

Norway, Denmark, Iceland, Austria, Romania and Italy stopped shooting. Thailand became the first Asian country to stop using the company’s vaccine last week, CNBC reported

Nearly five million Europeans received the vaccine until this past Wednesday.

Reuters reported that workers experienced issues related to blood clotting and other vascular issues.

Sigurd Hortemo with the Norwegian Medicines Agency told reporters in a media interview with members of the Norwegian Institute of Public Health that each of the hospitalized health care workers was under 50 years old, but said that the hospitalizations could not be precisely attributed to the shooting.

Steinar Madsen, medical director at the Norwegian Medicines Agency, told regional media that the affected individuals were seriously ill after receiving the shots.

“They have unusual symptoms: bleeding, hemorrhage and a low number of blood platelets,” Madsen said, according to Reuters. “They’re a little sick … We’re serious about it.”

Reuters reported that no such issues were reported during the vaccination clinical trials.

AstraZeneca defended the vaccine while pointing out that hospitalized patients may have experienced their symptoms with or without taking the single-shot vaccine.

“In fact, the reported number of these types of events for the COVID-19 AstraZeneca Vaccine does not exceed the number that naturally occurred in the undeveloped population,” the pharmaceutical giant said in a statement, according to BBC.

This article originally appeared on The Western Journal.

[ad_2]

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *